# Willett Advisors LLC

> Willett Advisors LLC is a VC fund backing Biotechnology and Therapeutics. See 22 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 22
- Last investment: Jan 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.willettadvisors.com

Willett Advisors LLC is a VC fund in New York focused on Biotechnology and Therapeutics. Willett Advisors LLC manages the philanthropic assets of Michael R. Bloomberg, including the assets of Bloomberg Philanthropies. The firm’s objective is to achieve long-term capital appreciation through the construction of a diversified investment portfolio.

## Contacts

5 contacts available for Willett Advisors LLC. Shizune tracks 2 team members at Willett Advisors LLC. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/willett-advisors-llc?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 50% |
| Therapeutics | 9 | 41% |
| Health Care | 8 | 36% |
| Medical | 4 | 18% |
| Life Science | 3 | 14% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 23% |
| Series D | 4 | 18% |
| Series A | 2 | 9% |
| Series C | 2 | 9% |
| Series E | 2 | 9% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 59% |
| Italy | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Brian Allen | Director of Private Equity | 0 | https://shizune.co/investors/profile/brian-allen-8716 |
| Steven Rattner | Chairman and Chief Executive Officer | 1 | https://shizune.co/investors/profile/steven-rattner |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cellares | Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $257M | Series D | Jan 28, 2026 |  |
| Kinaset Therapeutics | Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M | Series B | Jan 10, 2026 |  |
| AAVantgarde Bio | AAVantgarde Bio is developing gene therapies for inherited retinal disorders. | $141M | Series B | Nov 03, 2025 |  |
| Antares Therapeutics | Antares Therapeutics is a biotechnology company focused on developing transformational precision medicines targeting validated but previously undruggable targets in cancer and other serious diseases with significant unmet medical needs. Founded as a spin-out from Scorpion Therapeutics, it leverages proprietary drug discovery capabilities and arobust preclinical pipeline to advance multiple programs, primarily in precision oncology. | $177M | Series A | May 15, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M |  | Apr 03, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M | Series F | Apr 03, 2025 |  |
| Scorpion Therapeutics | Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purposemodel to efficiently unlock the next generation of precision oncology. | $150M | Series C | Jul 16, 2024 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $120M | Series E | Feb 08, 2024 |  |
| Remix Therapeutics | Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. | $60M | Venture - Series Unknown | Jan 03, 2024 |  |
| Carmot Therapeutics | Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California. | $150M | Series E | May 25, 2023 |  |

10 of 22 investments shown.

## Co-investors
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 7 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 6 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 5 deals together
- [Schroders Capital](https://shizune.co/investors/profile/schroders-capital) — VC Fund, 5 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 4 deals together
- [Avenir](https://shizune.co/investors/profile/avenir-growth-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Willett Advisors LLC invest in?

Willett Advisors LLC invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Series D stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Willett Advisors LLC?

Public channels for Willett Advisors LLC include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Willett Advisors LLC?

The team at Willett Advisors LLC includes Brian Allen (Director of Private Equity) and Steven Rattner (Chairman and Chief Executive Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co